Heyholder
‹ Activism FilingsMajor

L&K BIOMED CO., LTD. Q3 profit from main business KRW 0.9 billion, up 156.6% from a year earlier; sales KRW 12.2 billion

L&K BIOMED CO., LTD.· Periodic Report

AI summary · Not investment advice

L&K Biomed sold KRW 12.2 billion in Q3 and earned KRW 0.9 billion from its main business, up 156.6% from a year earlier and down 31.9% from the previous quarter.

Operating profit · 3 months

KRW 867.9 million

Key facts

Revenue (3 months)
KRW 12.2 billion
Net income (3 months)
KRW -11.0 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 10.1 billion
Revenue (year to date)
KRW 33.5 billion
Operating profit (prior-year 3 months)
KRW 338.3 million
Operating profit (year to date)
KRW 2.2 billion
Net income (prior-year 3 months)
KRW 2.6 billion
Net income (year to date)
KRW 4.9 billion

Commentary

AI commentary · Not investment advice

What happened

L&K Biosciences reported its 3rd-quarter results on a consolidated basis. Sales for the 3 months were KRW 12.24 billion, and operating profit (profit from its main business) was KRW 868 million.

In the company's terms

Sales for the 3 months rose 21.2% from the same period a year earlier. They rose 4.3% from the previous quarter.

What changes for shareholders

Operating profit for the 3 months rose 156.6% from a year earlier. It fell 31.9% from the previous quarter.

Net income (final profit after all costs) for the 3 months was a loss of KRW 11.05 billion. The previous quarter showed a profit, so this is a swing to a loss. A year earlier, the 3 months showed net income of KRW 2.58 billion.

For the year to date, sales were KRW 33.47 billion. Operating profit was KRW 2.25 billion. Net income was KRW 4.86 billion.

Comments

No comments yet

Comments from shareholders will appear here.